Beijing Guaran Science and Technology

Beijing Guaran Science and Technology is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of adeno-associated virus (AAV) mediated gene therapies. The company's primary focus is on treating ophthalmic disorders, specifically inherited retinal diseases (IRDs) and age-related macular degeneration. Its lead candidate, GRN-001, is an AAV-based gene therapy designed to treat Leber Congenital Amaurosis type 2 (LCA2) by delivering a functional copy of the RPE65 gene. Guaran leverages a proprietary technology platform for vector optimization and large-scale GMP manufacturing to support its clinical pipeline. The company has successfully raised multiple rounds of financing from prominent investors such as Legend Capital and Northern Light Venture Capital. Guaran aims to address significant unmet medical needs in the field of genetic vision loss through one-time curative interventions.